Holen Sie sich die Stockscreener-App
54.20
29.26%
12.27
Handel nachbörslich:
55.48
1.28
+2.36%
Schlusskurs vom Vortag:
$41.93
Offen:
$44.16
24-Stunden-Volumen:
6.90M
Relative Volume:
6.91
Marktkapitalisierung:
$4.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-42.67
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
+29.70%
1M Leistung:
+29.85%
6M Leistung:
+100.44%
1J Leistung:
+77.94%
1-Tages-Spanne:
$43.25
$57.40
1-Wochen-Bereich:
$39.14
$57.40
52-Wochen-Spanne:
$14.80
$57.40
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
54.20 | 3.38B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating - TipRanks
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade
CG Oncology stock price target raised to $93 from $89 at Morgan Stanley - Investing.com Canada
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology - TipRanks
CG Oncology rises after expediting a late-stage trial readout for lead asset - Seeking Alpha
Midday Stock Roundup: loanDepot Rises on Trump Move - Orange County Business Journal
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026 - TechStock²
CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target - TipRanks
CG Oncology to Share Data From Phase 3 Bladder Cancer Trial a Year Ahead of Schedule; Shares Up - MarketScreener
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighTime to Buy? - MarketBeat
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Cg Oncology stock hits 52-week high at 46.19 USD By Investing.com - Investing.com India
CG Oncology stock soars after Phase 3 trial data timeline accelerated - Investing.com
Why CG Oncology Stock Is Sliding Despite Trial Boost - TipRanks
CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline - TipRanks
Cg Oncology provides updated timeline for Pivot-006 phase 3 topline data in intermediate-risk NMIBC - MarketScreener
CG Oncology accelerates timeline for bladder cancer trial data By Investing.com - Investing.com India
CG Oncology, Inc. Announces Expedited Timeline for PIVOT-006 Phase 3 Data - TradingView — Track All Markets
CG Oncology Announces Expedited Timeline for Phase 3 PIVOT-006 Trial Data on Cretostimogene for Intermediate-Risk NMIBC - Quiver Quantitative
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - The Manila Times
Bladder cancer trial to deliver key results nearly a year early - Stock Titan
CG Oncology, Inc. (NASDAQ:CGON) Nasdaq 100 Index Early-Stage Biotech - Kalkine Media
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is CG Oncology Inc. stock trading at a premium valuationJuly 2025 Spike Watch & AI Driven Price Forecasts - ulpravda.ru
Aktis raises $318M in 2026’s first biotech IPO - BioPharma Dive
Will CG Oncology Inc. stock split again soonQuarterly Portfolio Report & Weekly Breakout Watchlists - ulpravda.ru
Can CG Oncology Inc. stock maintain growth trajectoryJuly 2025 Highlights & Low Risk Profit Maximizing Plans - ulpravda.ru
Why analysts upgrade CG Oncology Inc. stockTake Profit Strategies & Free Robust Financial Gains - ulpravda.ru
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
CG Oncology (NASDAQ:CGON) Shares Down 6.3%Here's What Happened - MarketBeat
Big Picture: Is CG Oncology Inc stock trading at a premium valuationEarnings Beat & Community Trade Idea Sharing Platform - moha.gov.vn
CG Oncology Earnings Notes - Trefis
Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Piper Sandler initiates coverage of oncology companies - MSN
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN) - Seeking Alpha
CG Oncology Appoints Christina Rossi to Board - MSN
CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha
CG Oncology, Inc. (CGON): Investor Outlook Reveals 76% Potential Upside In Biotech Stock - DirectorsTalk Interviews
CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating - TipRanks
SUO-CTC CG Oncology NMIBC Research Fellowship - Oncodaily
Will CG Oncology Inc. stock continue upward momentum2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC DataWhat's Changed - Sahm
Why CG Oncology Inc. stock is in analyst buy zoneMarket Rally & Real-Time Volume Trigger Notifications - DonanımHaber
Is CG Oncology Inc. stock supported by strong cash flows2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will CG Oncology Inc. stock beat EPS estimatesJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Aug Summary: Why analysts upgrade CG Oncology Inc. stockChart Signals & Weekly High Return Opportunities - Улправда
Is CG Oncology Inc. stock a safe investment in uncertain marketsGold Moves & Low Risk Growth Stock Ideas - Улправда
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):